ATE313799T1 - Nachweis von hla-g - Google Patents

Nachweis von hla-g

Info

Publication number
ATE313799T1
ATE313799T1 AT00963825T AT00963825T ATE313799T1 AT E313799 T1 ATE313799 T1 AT E313799T1 AT 00963825 T AT00963825 T AT 00963825T AT 00963825 T AT00963825 T AT 00963825T AT E313799 T1 ATE313799 T1 AT E313799T1
Authority
AT
Austria
Prior art keywords
hla
antibodies
disclosed
detection
bind
Prior art date
Application number
AT00963825T
Other languages
English (en)
Inventor
Clifford L Librach
Shang-Mian Yie
Original Assignee
Clifford L Librach
Shang-Mian Yie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clifford L Librach, Shang-Mian Yie filed Critical Clifford L Librach
Application granted granted Critical
Publication of ATE313799T1 publication Critical patent/ATE313799T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/906—Fertility tests
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y10S530/852—Sperm
    • Y10S530/853—Ovary; eggs; embryos

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Insulating Materials (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
AT00963825T 1999-09-27 2000-09-27 Nachweis von hla-g ATE313799T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40705699A 1999-09-27 1999-09-27
PCT/CA2000/001116 WO2001023893A2 (en) 1999-09-27 2000-09-27 Detection of hla-g

Publications (1)

Publication Number Publication Date
ATE313799T1 true ATE313799T1 (de) 2006-01-15

Family

ID=23610425

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00963825T ATE313799T1 (de) 1999-09-27 2000-09-27 Nachweis von hla-g

Country Status (7)

Country Link
US (1) US6613538B2 (de)
EP (1) EP1224465B1 (de)
AT (1) ATE313799T1 (de)
AU (1) AU780825B2 (de)
CA (1) CA2386066C (de)
DE (1) DE60025022D1 (de)
WO (1) WO2001023893A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126829A1 (en) * 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
US20050118563A1 (en) * 2003-08-28 2005-06-02 Geoffrey Sher Method for determining embryo quality
US20050241013A1 (en) * 2004-04-22 2005-10-27 Geoffrey Sher Unique use of sHLA-G obtained in soluble form from JEG-3 cell line, by purification by PCR, HPLC, or any other techniques, as well as in other forms, as an implantation promoting agent when added to embryo culture and/or to the media in which embryos are transferred to the uterus following in vitro fertilization
JP2009524829A (ja) * 2006-01-27 2009-07-02 イースタン バージニア メディカル スクール ヒトｉｖｆ由来胚のプロテオームフィンガープリンティング：発生能のバイオマーカーの同定法
ATE454632T1 (de) 2006-04-20 2010-01-15 Northern Sydney And Central Co Verfahren zur beurteilung der lebensfähigkeit von embryos
EP2670868A4 (de) * 2011-01-31 2015-05-06 Esoterix Genetic Lab Llc Verfahren zur anreicherung von mikropartikeln oder nukleinsäuren mittels bindungsmolekülen
CN107530427A (zh) 2015-03-27 2018-01-02 南加利福尼亚大学 针对用于实体肿瘤的治疗的lhr的car t细胞疗法
US20190119385A1 (en) * 2015-03-27 2019-04-25 University Of Southern California Hla-g as a novel target for car t-cell immunotherapy
TW201829463A (zh) * 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
CN113045656B (zh) * 2020-07-27 2022-03-08 台州恩泽医疗中心(集团) 抗hla-g异构体分子hla-g5及hla-g6的单克隆抗体及其用途
CN115819583B (zh) * 2022-03-31 2026-03-03 台州恩泽医疗中心(集团) 一种抗hla-g分子的单克隆抗体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11503320A (ja) * 1995-04-07 1999-03-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｈｌａ−ｇ検出用抗体
AU2636399A (en) * 1998-02-25 1999-09-15 National University Of Ireland, Cork Hla linked pre-eclampsia and miscarriage susceptibility gene
JP4544498B2 (ja) * 1998-11-16 2010-09-15 エスキューアイ・ダイアグノスティクス・システムズ・インコーポレイテッド 生物学的サンプルの分析装置および方法

Also Published As

Publication number Publication date
AU780825B2 (en) 2005-04-21
CA2386066C (en) 2004-12-21
CA2386066A1 (en) 2001-04-05
US20020015973A1 (en) 2002-02-07
WO2001023893A2 (en) 2001-04-05
US6613538B2 (en) 2003-09-02
WO2001023893A3 (en) 2001-05-17
DE60025022D1 (de) 2006-01-26
EP1224465A2 (de) 2002-07-24
AU7500600A (en) 2001-04-30
EP1224465B1 (de) 2005-12-21

Similar Documents

Publication Publication Date Title
PT1190257E (pt) Deteccao precoce dos flavivirus, utilizando a glicoproteina ns1
ATE313799T1 (de) Nachweis von hla-g
ATE396264T1 (de) Zytokinrezeptoruntereinheit-proteine aus säugetieren, damit zusammenhängende reagenzien und methoden
ES2293973T3 (es) Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
EP2305715A3 (de) Monoklonaler Antikörper gegen das Osteoprotegerin-bindenden Protein
DE60115405D1 (de) Verbesserungen in bezug auf ribosom-komplexe als selektionspartikel
WO2002020569A3 (en) Mammalian genes; related reagents and methods
WO2001090358A3 (en) Mammalian receptor proteins; related reagents and methods
DK1692181T3 (da) Leptinantagonist og fremgangsmåde til kvantitativ måling af leptin
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
DE60232248D1 (de) Schwangerschaftsnachweisverfahren
EP1433792A3 (de) Menschlische-rezeptor Proteine; verwandte Reagenzien und Methoden
BR9709958A (pt) Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso
WO2001061305A3 (en) Immunoassays detecting or making use of at least two rubber latexallergens
IL157047A0 (en) Methods and devices for quantitation of glycated protein
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
EP2365002A3 (de) Zusammensetzung zur Behandlung einer Krankheit, die mit MSRV/HERV-W assoziiert ist
WO2002090989A3 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
WO2000039154A3 (de) Peptide des at1-rezeptors und ihre verwendung bei präeklampsie und maligner hypertonie
MXPA02011906A (es) Ensayo, equipo y procedimiento a base de esferas no lavables.
Fox Measurement of streptococcal antigen synthesis with fluorescent antibody.
EP1319089A4 (de) In vitro testverfahren zur bestimmung der immunogenizität eines impfstoffes
AU2001295423A1 (en) Indirect method for the quantitative analysis of the binding capacity present in an aqueous protein solution
WO2002078635A3 (en) Estrogen receptor modulators

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties